Altitude Crest Partners’s Eli Lilly LLY Stock Holding History

Altitude Crest Partners’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9,200	Closed	-$7.16M	–	20
2024 Q1	$7.16M	Buy	+9,200	New	+$6.55M	3.06%	11

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Altitude Crest Partners's LLY Position: Q2 2024 in Review

Altitude Crest Partners sold out of Eli Lilly (LLY) in Q2 2024, closing a stake of 9,200 shares — an estimated $7.16M sold.

Altitude Crest Partners first reported a position in LLY in Q1 2024 and held it in 1 quarter. The position peaked at $7.16M in Q1 2024. 3,564 funds tracked by Wall St. Rank hold LLY as of Q2 2024.

Altitude Crest Partners reported no remaining Eli Lilly position as of Q2 2024 after selling out during the quarter.
Altitude Crest Partners sold 9,200 Eli Lilly shares in Q2 2024, an estimated $7.16M.
Altitude Crest Partners first reported a position in Eli Lilly in Q1 2024 and held it in 1 quarter.
Altitude Crest Partners's Eli Lilly position peaked at $7.16M in Q1 2024.
3,564 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.